Research programme: biologic therapeutics - Merck/NGM BiopharmaceuticalsAlternative Names: NP 201; NP201 - NGM Biopharmaceuticals
Latest Information Update: 27 Feb 2015
At a glance
- Originator NGM Biopharmaceuticals
- Class Peptides; Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Metabolic disorders; Non-alcoholic steatohepatitis